C
Gilead Sciences, Inc. GILD
$98.16 -$0.74-0.75% NASDAQ
Recommendation
Prev Close
$98.90
Volume
12,994,843
Avg Vol (90D)
8,662,083
Market Cap
$123.29B
Dividend & Yield
$3.10(3.13%)
52-Week Range
$62.07 - $119.96
P/E (TTM)
278.67
EPS (TTM)
$0.3549
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
5/2/2025 - MarketBeat
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
5/9/2025 - GuruFocus
Gilead Sciences (GILD) Announces Results of 2025 Annual Stockholders Meeting
5/8/2025 - GuruFocus
Gilead Sciences Holds Annual Stockholders Meeting
5/8/2025 - TipRanks Financial Blog
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
5/8/2025 - GuruFocus
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
5/8/2025 - Accesswire
Cahill Financial Advisors Inc. Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
5/8/2025 - MarketBeat
Gilead Sciences (GILD) Boosts U.S. Investment by $11 Billion
5/7/2025 - GuruFocus
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025
5/7/2025 - Simply Wall St
See Which Of The Latest 13F Filers Holds GILD
5/7/2025 - Holdings Channel
Implied ONEY Analyst Target Price: $119
5/7/2025 - ETF Channel
Captrust Financial Advisors Acquires 96,271 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
5/7/2025 - MarketBeat
21,600 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Bayesian Capital Management LP
5/7/2025 - MarketBeat
Bearing Point Capital LLC Invests $588,000 in Gilead Sciences, Inc. (NASDAQ:GILD)
5/7/2025 - MarketBeat
Benjamin Edwards Inc. Has $16.27 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)
5/7/2025 - MarketBeat
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
5/7/2025 - Business Wire
Gileads Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
5/7/2025 - Business Wire
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
5/6/2025 - Accesswire
Brown Advisory Inc. Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
5/6/2025 - Ticker Report
BNP Paribas Sells 2,996 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
5/6/2025 - MarketBeat
Alteri Wealth LLC Acquires New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
5/6/2025 - MarketBeat
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
5/5/2025 - Zacks Investment Research
25,031 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by BLI Banque de Luxembourg Investments
5/5/2025 - Ticker Report
Ariel Investments LLC Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)
5/5/2025 - MarketBeat
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
4/1/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$28.75B
EBITDA (TTM)
$13.43B
EBIT (TTM)
$10.66B
Net Income (TTM)
$480.00M
Balance Sheet
Total Assets (Q)
$59.00B
Total Debt (Q)
$27.32B
Total Liabilities (Q)
$39.75B
Book Value Per Share (Q)
$15.51
Cash Flow
Cash from Operations (TTM)
$10.83B
Cash from Investing (TTM)
-$3.45B
Cash from Financing (TTM)
-$3.43B
Net Change in Cash (TTM)
$3.91B
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.29
7-Day Total Return
-5.81%
30-Day Total Return
-10.17%
60-Day Total Return
2.82%
90-Day Total Return
4.70%
Year to Date Total Return
7.59%
1-Year Total Return
56.88%
2-Year Total Return
34.69%
3-Year Total Return
78.87%
5-Year Total Return
55.03%
52-week Low
May 31, 2024 - $62.07
52-week High
Mar 10, 2025 - $119.96
Valuation
Market Cap
$123.29B - Large Cap
Enterprise Value
$140.38B
Price/Sales (TTM)
4.33
Price/Book (Q)
6.38
Dividends and Shares
Shares Outstanding
1.26B
Dividend Per Share (Most Recent)
$0.79
Dividend Per Share (TTM)
$3.10
Corporate Info
Website
www.gilead.com
Phone Number
650 574 3000
Address
333 Lakeside Drive
Foster City, CA 94404
Country
United States
Year Founded
1987
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The... more
NASDAQ 05/08/2025 4:00PM Eastern Quotes delayed